- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01116024
ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000 (Enable)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria
- Medical University of Vienna
-
-
-
-
-
Frankfurt, Germany
- Johann Wolfgang Goethe University
-
Freiburg, Germany
- University Medical Center Freiburg
-
Kiel, Germany
- University Medical Center Kiel
-
Lubeck, Germany
- UKSH, Campus Lübeck
-
-
-
-
-
Gdansk, Poland
- Medical University of Gdansk
-
Krakow, Poland
- Jagiellonian University
-
-
-
-
-
Basel, Switzerland
- Cardiac Surgery University Hospital Basel
-
Bern, Switzerland
- Inselspital Bern
-
-
-
-
-
Oxford, United Kingdom
- John Radcliffe Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve repair. (The three remaining valves must be of native tissue).
- The patient is geographically stable and willing to return to the implant site for follow-up visits.
- The patient has been adequately informed of risks and requirements and consent to his/her participation in the clinical study.
- If this patient is female and of childbearing potential, patient has a negative pregnancy test within seven (7) days prior to the study procedure.
Exclusion Criteria:
- The patient requires replacement of two or more valves.
- The patient is < 20 years of age.
- The patient has a non-cardiac major or progressive disease, which in the Investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 24 months.
- The patient is an intravenous drug and/or alcohol abuser.
- The patient presents with active endocarditis or other systemic infection.
- The patient has had previous valve replacement surgery, including previous implant and then explant of the ATS 3f Enable Aortic Bioprosthesis (Model 6000) or placement of a rigid annuloplasty ring in the mitral position.
- The patient is participating in concomitant research studies of investigational products.
- The patient presents with dilatation of the ascending aorta, Marfan Syndrome, Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the ascending aorta to be irregular in geometry or physiology as seen via preoperative imaging.
- The patient has chronic renal failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3f Enable Aortic Bioprosthesis Model 6000
Single arm study
|
Replacement Aortic Heart Valve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thromboembolism/Thrombosis
Time Frame: Five Years
|
Valve related thromboembolism and valvular thrombosis. Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year) |
Five Years
|
Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)
Time Frame: Five Years
|
Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy. Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant): Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Paravalvular Leaks (All and Major)
Time Frame: Five Years
|
Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Endocarditis
Time Frame: Five Years
|
Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Hemolysis
Time Frame: Five Years
|
Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred.
Hemolysis in subjects with tissue valves - as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis - is usually associated with paravalvular leakage or infection.
|
Five Years
|
Structural Valve Deterioration
Time Frame: Five Years
|
Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation. There were no cases of structural deterioration reported for the study. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Non-Structural Dysfunction
Time Frame: Five Years
|
Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Re-operation, Explant, Repair
Time Frame: Five Years
|
Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant. The results are reported as linearized rate (percentage of participants per patient-year). |
Five Years
|
Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance
Time Frame: Five Years
|
New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies. Class I: Patients with cardiac disease but without limitations of ordinary activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased. |
Five Years
|
Hemodynamic
Time Frame: Five Years
|
Mean and peak pressure gradients from discharge through 5 years follow up.
The gradient represents the difference in blood pressure across the valve.
|
Five Years
|
Hemodynamics - Effective Orifice Area
Time Frame: Five Years
|
Effective orifice area (EOA) data. The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve. |
Five Years
|
Hemodynamics - Effective Orifice Area Index
Time Frame: Five Years
|
The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.
|
Five Years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Eric Vang, Medtronic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S2005 Rev. 17-MAY-2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Valve Diseases
-
National Heart, Lung, and Blood Institute (NHLBI)WithdrawnHeart Failure | Aortic Valve Stenosis | Mitral Valve Regurgitation | Heart Valve Disease | Tricuspid Valve RegurgitationUnited States
-
Boston Children's HospitalRecruitingValve Disease, Heart | Valve Heart Disease | Valve Disease, AorticUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
-
UMC UtrechtLeiden University Medical Center; The Interuniversity Cardiology Institute... and other collaboratorsTerminatedMitral Valve Insufficiency | Diseases of Mitral Valve | Heart; Disease, Mitral(Valve)Netherlands
-
Edwards LifesciencesRecruitingCardiovascular Diseases | Heart Failure | Heart Valve Diseases | Tricuspid Valve Regurgitation | Tricuspid Valve Insufficiency | Tricuspid Valve DiseaseUnited States, Germany
-
Synecor, LLCUnknownHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Disease
-
Edwards LifesciencesActive, not recruitingHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve DiseaseUnited States, Australia, Brazil
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
-
Caisson Interventional LLCActive, not recruitingMitral Regurgitation | Valve Disease, Heart | Valve Heart Disease | Mitral Valve Disease | Mitral Valve Failure | Mitral DiseaseUnited States
-
Universitätsklinikum Hamburg-EppendorfRecruitingAortic Valve Disease | Heart Valve Diseases | Mitral Valve Disease | Tricuspid Valve DiseaseGermany
Clinical Trials on ATS 3f Enable Aortic Bioprosthesis Model 6000
-
Medtronic Bakken Research CenterCompletedAortic Valve Stenosis | Aortic Valve InsufficiencyGermany, Spain, Switzerland, Italy, United Kingdom, Netherlands, France
-
Medtronic CardiovascularTerminated
-
Medtronic CardiovascularTerminatedHeart Valve DiseasesUnited States, Canada
-
Medtronic CardiovascularWithdrawn
-
Medtronic Cardiac SurgeryMedtronicActive, not recruitingAortic StenosisFrance, United States, Germany, Switzerland, Canada, Netherlands, Italy, United Kingdom
-
Edwards LifesciencesCompletedPulmonary Valve Insufficiency | Pulmonary Valve Degeneration | Congenital Pulmonary Valve AbnormalityUnited States